Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Description

This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients (Arm A) or future HSCT recipients (Arm B) for the treatment of high-risk or relapsed or refractory hematopoietic malignancies. In addition to safety, this study will also evaluate if event-free survival (EFS) is improved with TAA-T administration at six months after HSCT for patients with high risk AML and MDS (Arm C).This Phase I dose-escalation trial is designed to evaluate the safety of administering rapidly -generated tumor multi-antigen associated -specific cytotoxic T lymphocytes, to HSCT recipients (Arm A) or future HSCT recipients (Arm B) for the treatment of high-risk or relapsed or refractory hematopoietic malignancies. In addition to safety, this study will also evaluate if event-free survival (EFS) is improved with TAA-T administration at six months after HSCT for patients with high ris

Trial Eligibility

Recipient procurement Inclusion criteria: * Aged 6 months to 80 years * Received prior or anticipated myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant * Patients (Arm A) who have undergone allo-HSCT with high risk or relapse or residual/recurrent disease (see below) OR patients (Arm B) with high risk or relapsed/refractory disease (\> 2 regimens with greater than M1 marrow or persistent HD) with anticipated allo-HSCT: * Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Ambiguous lineage leukemia or lymphoma, Chronic Myelogenous leukemia (CML), CMML, MDS: * Evidence of active leukemia or lymphoma disease by flow cytometry, morphology, or cytogenetic evaluation within the marrow or extramedullary sites. * Hodgkin's Lymphoma that has failed or are intolerant of Brentuximab, Non-Hodgkin Lymphoma (NHL) including Grey Zone Lymphoma, Anaplastic large cell lymphoma (ALCL), and mantle cell lymphoma: * Evidence of lymphoma by morphology, Positron Emission Tomography (PET)/ Computed tomography (CT) uptake in a site of previous disease in the absence of other etiologies. * ARM C only includes patients with high risk AML and MDS who have received an allo-HSCT and have not had hematologic relapse of disease. * Karnofsky/Lansky score of ≥ 50 * Agree to use contraceptive measures during study protocol participation (when age appropriate) * Patient or parent/guardian capable of providing informed consent. * T cell chimerism \> 94% if collected from recipient of allo-HSCT (performed within the last 6 months) * If the product is procured from the recipient in the autologous (Arm B) setting, the absolute lymphocyte count should be greater than or equal to 600 for procurement. Please note: If a patient has already undergone an allogeneic HSCT, it is NOT allowed to generate TAA-T from patient blood collected post-HSCT under Arm A or C Recipient Procurement Exclusion Criteria: * Patients with uncontrolled infections * Current evidence of GVHD \> grade 2 or bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis Pregnancy or lactating (female of childbearing potential) Recipient Inclusion criteria for initial TAA-T administration and for subsequent infusions * Patients (Arm A) who have undergone allo-HSCT with high risk or relapse or residual/recurrent disease (see below) OR patients (Arm B) with high risk or relapsed/refractory disease (\> 2 regimens with greater than M1 marrow or persistent HD) with anticipated allo-HSCT: o Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Ambiguous lineage leukemia or lymphoma, Chronic Myelogenous leukemia (CML), CMML, MDS: Evidence of active leukemia or lymphoma disease by flow cytometry, morphology, or cytogenetic evaluation within the marrow or extramedullary sites. o Hodgkin's Lymphoma that has failed or are intolerant of Brentuximab, NHL including Grey Zone Lymphoma, ALCL, and mantle cell lymphoma: Evidence of lymphoma by morphology, PET/CT uptake in a site of previous disease in the absence of other etiologies. o ARM C only includes patients with high risk AML and MDS who have received an allo-HSCT and have not had hematologic relapse of disease. * Steroids less than 0.5 mg/kg/day prednisone or equivalent. * Karnofsky/Lansky score of ≥ 50. * Bilirubin \< 2.5 mg/dL, AST/ALT \<5x upper limit of normal, Serum creatinine \< 1.0 or 2x the upper limit of normal (whichever is higher). * Pulse oximetry of \> 90% on room air. * Absolute neutrophil count \> 250/ µL (may be supported with Granulocyte colony-stimulating factor (GCSF)). * Agree to use contraceptive measures during study protocol participation (when age appropriate). * Patient or parent/guardian capable of providing informed consent. * LVEF \> 50% or LVSF \> 27% (performed within the last 6 months) if history of TBI \>500 cGy for arm A and B. * Total chimerism \> 50%; or if cancer cells preclude this, donor T cell chimerism \> 50% (performed within the last 6 months). Recipient Exclusion criteria for initial and subsequent TAA-T infusions * Patients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies within 28 days prior to TAA-T infusion. * No investigational therapies (under IND, not extensively studied in the current clinical context) within 28 days prior to TAA-T infusion. For allogeneic HSCT recipients PD-1 inhibitors or other T cell activating agents will be excluded. For Arm B, if the patient has tolerated these agents without autoimmunity, these may be continued with the TAA-T infusion. * Uncontrolled infections * Active Bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis * Current evidence of GVHD \> grade 2 for Arm A and B; Active GVHD of any grade is exclusion for arm C patients. * Pregnancy or lactating (female of childbearing potential)

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to support you by reviewing the eligibility criteria to see if you might qualify for this trial.